Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen.
- An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen.
- Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and will continue to develop and commercialize these medicines as planned.
- In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual property rights related to Daiichi Sankyos ADC technology.
- In response, Seagen filed an arbitration demand in connection with the dispute with the American Arbitration Association in the same month, resulting in an arbitration and todays decision.